Compare Solstice Advanced Materials Inc. Common Stock (SOLS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Solstice Advanced Materials Inc. Common Stock vs Zimmer Biomet Holdings Inc — how do they compare? Solstice Advanced Materials Inc. Common Stock trades at $59.92 (market cap $9.55B), while Zimmer Biomet Holdings Inc trades at $92.24 (market cap $17.50B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.05%). Which is the better fit depends on your goals — on Pluang, investors hold Solstice Advanced Materials Inc. Common Stock for 0 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| SOLS | ZBH | |
|---|---|---|
Market Cap | $9.55B | $17.50B |
Volume | 2,661,277 | 1,890,029 |
Sector | Basic Materials | Health |
52-Week High | $88.60 | $103.98 |
52-Week Low | $41.43 | $79.58 |
Typical Hold Time | 0 Days | 89 Days |
Enterprise Value | $11.23B | $24.57B |
Dividend Yield | 0.5% | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Solstice Advanced Materials (SOLS) trades at $60.91, up 0.33% with neutral technical signals. The company shows strong profitability with 30.64% gross margins and 14.95% ROE, though Q4 2025 earnings missed expectations. Recent developments include a $49M R&D expansion and termination of the Element Solutions merger, with the board authorizing a $500M share repurchase program. Analyst consensus is bullish with 80% buy ratings and a $80.22 price target representing 32% upside potential.
SOLS presents a compelling growth story with consistent earnings beats and institutional accumulation, though elevated P/E of 46.07 warrants caution. Key risks include execution challenges post-merger termination and margin pressure as profit margins declined from 6.09% to 5.12% year-over-year. The stock offers substantial upside if management delivers on growth initiatives while maintaining current profitability levels.
Zimmer Biomet (ZBH) trades at $92.08, down 0.1% on the day, with a bullish technical outlook supported by moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 8.56%. A quarterly dividend of $0.24 was recently declared, payable in October 2026.
The investment outlook is cautiously optimistic, driven by earnings beats and analyst consensus pointing to upside. Key risks include rising debt levels and competitive pressures. The consensus price target of $103.11 suggests potential appreciation, but investors should weigh margin trends and macroeconomic factors affecting healthcare spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Solstice Advanced Materials Inc. Common Stock
Solstice Advanced Materials Inc. is a specialty materials company spun off from Honeywell in 2025, producing low-global-warming-potential refrigerants, blowing agents, and industrial solvents through its Refrigerants and Applied Solutions segment. Its Electronic and Specialty Materials segment supplies semiconductor materials, high-strength fibers, and healthcare-packaging films.
Read more on SOLS →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
